Components of Placebo Effect: Randomised Controlled Trial in Patients with Irritable Bowel Syndrome

被引:0
|
作者
Hummelsberger, J. [1 ]
机构
[1] Chinese Med SMS Societas Med Sinensis, Int Soc, Hackenstr 7 C, D-80331 Munich, Germany
来源
DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR | 2010年 / 53卷 / 02期
关键词
D O I
10.1016/j.dza.2010.04.011
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: To investigate whether placebo effects can experimentally be separated into the response to three components - assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient- practitioner relationship - and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. Design: A six week single blind three arm randomised controlled trial. Setting Academic medical centre. Participants 262 adults (76 % women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of >= 150 on the symptom severity scale. Interventions: For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient- practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. Main outcome measures Global improvement scale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life. Results: At three weeks, scores on the global improvement scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for waiting list versus "limited" versus "augmented," respectively (P < 0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28 % on waiting list, 44 % in limited group, and 62 % in augmented group (P < 0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P < 0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P < 0.001). All pairwise comparisons between augmented and limited patient- practitioner relationship were significant: global improvement scale (P < 0.001), adequate relief of symptoms (P < 0.001), symptom severity score (P = 0.007), quality of life (P = 0.01). Results were similar at six week follow-up. Conclusion Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient- practitioner relationship is the most robust component.
引用
收藏
页码:41 / 42
页数:3
相关论文
共 50 条
  • [31] Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome
    Rees, G
    Davies, J
    Thompson, R
    Parker, M
    Liepins, P
    JOURNAL OF THE ROYAL SOCIETY FOR THE PROMOTION OF HEALTH, 2005, 125 (01): : 30 - 34
  • [32] A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome
    Roberts, Lesley M.
    McCahon, Deborah
    Holder, Roger
    Wilson, Sue
    Hobbs, F. D. Richard
    BMC GASTROENTEROLOGY, 2013, 13
  • [33] Effects of linseeds on the symptoms of irritable bowel syndrome: a pilot randomised controlled trial
    Cockerell, K. M.
    Watkins, A. S. M.
    Reeves, L. B.
    Goddard, L.
    Lomer, M. C. E.
    JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2012, 25 (05) : 435 - 443
  • [34] A randomised controlled trial of a probiotic ‘functional food’ in the management of irritable bowel syndrome
    Lesley M Roberts
    Deborah McCahon
    Roger Holder
    Sue Wilson
    FD Richard Hobbs
    BMC Gastroenterology, 13
  • [35] A CONTROLLED TRIAL OF PHYCOLOGICAL TREATMENT IN PATIENTS WITH THE IRRITABLE BOWEL SYNDROME
    GUTHRIE, EA
    CREED, FH
    DAWSON, D
    GUT, 1988, 29 (10) : A1481 - A1481
  • [36] A randomized controlled trial of imipramine in patients with irritable bowel syndrome
    Abdul-Baki, Heitham
    El Hajj, Ihab I.
    ElZahabi, Lara
    Azar, Cecilio
    Aoun, Elie
    Skoury, Assaad
    Chaar, Hani
    Sharara, Ala I.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (29) : 3636 - 3642
  • [37] A randomized controlled trial of imipramine in patients with irritable bowel syndrome
    Heitham Abdul-Baki
    Ihab I El Hajj
    Lara ElZahabi
    Cecilio Azar
    Elie Aoun
    Assaad Skoury
    Hani Chaar
    Ala I Sharara
    World Journal of Gastroenterology, 2009, 15 (29) : 3636 - 3642
  • [38] A randomized double-blind placebo-controlled trial of imipramine in patients with irritable bowel syndrome
    Abdul-Baki, Heitham
    El Zahabi, Lara M. N.
    ElHajj, Ihab I.
    Azar, Cecilio R.
    Skoury, Assaad
    Chaar, Hani F.
    Aoun, Elie
    Sharara, Ala I.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S479 - S479
  • [39] Effects of Ramosetron on Male Patients With Irritable Bowel Syndrome With Diarrhea: Randomized, Placebo-Controlled Trial
    Fukudo, Shin
    Ida, Motoko
    Akiho, Hikaru
    Nakashima, Yoshihiro
    Matsueda, Kei
    GASTROENTEROLOGY, 2013, 144 (05) : S545 - S545
  • [40] Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial
    Gunn, David
    Topan, Rabia
    Barnard, Lorna
    Fried, Ron
    Holloway, Ivana
    Brindle, Richard
    Corsetti, Maura
    Scott, Mark
    Farmer, Adam
    Kapur, Kapil
    Sanders, David
    Eugenicos, Maria
    Trudgill, Nigel
    Whorwell, Peter
    Mclaughlin, John
    Akbar, Ayesha
    Houghton, Lesley
    Dinning, Phil G.
    Aziz, Qasim
    Ford, Alexander C.
    Farrin, Amanda J.
    Spiller, Robin
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (11) : 1258 - 1271